Oral cancer to be detected by Point-Of-Care Biosensor
24 January 2023
Researchers at the University of Florida have created a point-of-care biosensor that can rapidly detect a biomarker for oral cancer. The device uses test strips, such as those used in blood glucose tests, to spot cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A), a protein biomarker that can reveal the presence of oral cancer. The device requires a liquid sample that is introduced to the end of the test strip, where it runs into channels that contain antibody-covered electrodes. The antibodies are specific for CIP2A, and antibody binding changes the electrical signal the electrodes produce, providing a readout if the protein is present. The technology could be useful in low resource or remote regions where access to conventional lab testing equipment is not available.
If oral cancers can be detected early, then the prognosis is frequently quite good. For instance, the researchers behind this latest technology report that oral cancers that are localised and approximately 2 centimeters or less in size can readily be treated and the corresponding five-year survival rates are over 90%. Moreover, such cancers are readily accessible in the oral cavity for clinicians to investigate and view them. These malignancies are therefore good candidates for a point-of-care diagnostic device that could be used in remote locations that do not have ready access to conventional diagnostics.
“Oral squamous cell carcinomas are one of the most common lip and oral cavity cancer types,” said Minghan Xian, a researcher involved in the study. “It requires early detection via various medical technologies to improve the survival rate. While most detection techniques for oral squamous cell carcinoma require histological testing in a lab to confirm the presence of cancer and cancer type, a point-of-care detection technique is preferred for on-site use and a quick result readout.”
The device includes electrodes that are covered in antibodies against CIP2A, providing a quick change in an electrical signal when the biomarker binds. In testing so far, the device proved to be highly sensitive, beating other detection techniques previously reported in the literature.
“Typically, test fluid is introduced into a small liquid channel on the tip of the sensor strips,” said Xian. “A few electrodes sit within the liquid channel, and the surface of these electrodes contain antibodies to specific proteins present within human oral cancer lesions. Short electrode pulses get sent through these electrodes during detection, and then the circuit board module analyses this signal and outputs a four-digit number that correlates to its concentration.”
Oral cancer can now be detected with the use of this biosensor. Your medical device company may be doing research or creating a new product. Therefore you require qualified people. Let our specialists assist you in finding the perfect match so that you have more time for other tasks. Learn more about how we can help you here!
Also published on: Medgadget.com
Want to stay informed about current Life Science and recruitment news on a regular base? Then register here for free.